Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 17, Issue 1, Pages 52-56Publisher
ELSEVIER SCI LTD
DOI: 10.1111/j.1469-0691.2010.03209.x
Keywords
Colombia; dissemination; Israel; Klebsiella pneumoniae; KPC-3
Categories
Funding
- AstraZeneca, Colombia
- Pfizer Inc., Groton, CT
- Merck Sharp & Dohme, Baxter, Colombia, Wyeth, Colombia
- Janssen, Colombia
Ask authors/readers for more resources
P>In 2008, an increase in the prevalence of carbapenem-resistant Klebsiella pneumoniae was noted in a 286-bed tertiary case hospital in Colombia, where 84 patients (32 infected and 52 colonized) had positive cultures. The identified index patient came from Israel for a liver transplantation. High level carbapenem resistance was observed. Polymyxin B and tigecycline were the only two antibiotics that remained active. PCR-restriction fragment length polymorphism analysis and sequencing revealed bla(KPC-3) in the major clone, which was indistinguishable from the K. pneumoniae carbapenemase-3-producing clone described previously in Israel. This exemplifies the threat posed by the global spread of K. pneumoniae carbapenemase-producing pathogens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available